Recent News for IGXT - Intelgenx Technologs

Date Title
Feb 11 IntelGenx Completes C$8.2 Million Equity Offering
Jan 27 IntelGenx Announces Pricing of Equity Offering
Jan 15 IntelGenx Receives Health Canada Authorization to Proceed with New Amendment for Montelukast VersaFilm® Phase 2a Trial
Jan 13 IntelGenx Provides Commercial Update on its Two Lead VersaFilm® Product Candidates, Cannabis-Infused Oral Film and RIZAPORT®
Jan 9 IntelGenx Enters Animal Health Market by Signing Feasibility Agreement for VetaFilm™ Platform
Dec 19 IntelGenx Files Preliminary Short Form Prospectus in Connection With a Proposed Offering of Units
Dec 6 IntelGenx Announces Issuance of Shares in Payment of Interest on Outstanding Debentures
Dec 3 IntelGenx to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference
Nov 7 IntelGenx Reports Third Quarter 2019 Financial Results
Nov 1 IntelGenx to Report Third Quarter 2019 Financial Results on November 7, 2019 – Conference Call to Follow
Oct 31 IntelGenx Initiates Scale-Up Work for Cannabis-Infused Oral Film Product
Oct 22 IntelGenx Announces FDA’s Acceptance of Resubmitted RIZAPORT® New Drug Application
Oct 9 IntelGenx Receives Positive DSMB Recommendation for Montelukast VersaFilm® Phase 2a Trial
Sep 27 IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA
Sep 26 IntelGenx Announces Resubmission of RIZAPORT® New Drug Application
Sep 3 IntelGenx to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Back to the Main IGXT Page...